Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

0534655 - BTÚ 2021 RIV AU eng J - Journal Article
Raninga, P. - Lee, A. - Sinha, D. - Dong, L.F. - Datta, K. - Lu, X. - Kalita-de Croft, P. - Dutt, M. - Hill, M. M. - Pouliot, N. M. - Gowda, H. - Kalimutho, M. - Neužil, Jiří - Khanna, K. K.
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
Theranostics. Roč. 10, č. 12 (2020), s. 5259-5275. ISSN 1838-7640. E-ISSN 1838-7640
R&D Projects: GA MZd(CZ) NV17-30138A
Institutional support: RVO:86652036
Keywords : stem-cell * multiple-myeloma * single-agent * phase-ii * bortezomib
OECD category: 3.1 Basic medicine
Impact factor: 11.556, year: 2020
Method of publishing: Open access
https://www.thno.org/v10p5259.htm

Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors induced minimal clinical response in breast cancer patients due to weak proteasome inhibition. Hence, developing effective targeted therapy using potent proteasome inhibitor is required.
Permanent Link: http://hdl.handle.net/11104/0312839